FOLH1 and triple-negative breast carcinoma: Given the increasing utilization of PSMA-based imaging agents, a substantial number of extraprostatic tissues manifesting elevated PSMA uptake have been detected, especially triple-negative breast cancer, providing novel prospective applications for PSMA radioligand therapy and imaging [41–44].